Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01036087
Title Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center

Her2-receptor negative breast cancer


Carboplatin + Nab-paclitaxel + Panitumumab

Cyclophosphamide + Epirubicin + Fluorouracil

Age Groups: adult
Covered Countries USA

No variant requirements are available.